Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 8/20 | 0.43 |
| ▸ | CDK2 | P24941 | 8/20 | 0.43 |
| ▸ | CDK4 | P11802 | 4/20 | 0.43 |
| ▸ | CDK1 | P06493 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.42 |
| ▸ | CCNE2 | O96020 | 7/20 | 0.42 |
| ▸ | CCND1 | P24385 | 3/20 | 0.42 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.42 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA3 | P07451 | 2/20 | 0.41 |
| ▸ | CA4 | P22748 | 2/20 | 0.41 |
| ▸ | CA6 | P23280 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4860224 | 0.85 | CCNE1 (0.44) | CCNE1CDK2CDK4CDK1LMNA | |
| SCHEMBL27174909 | 0.85 | FFAR2 (0.40) | CCNE1CDK2LMNAMEN1KMT2A | |
| SCHEMBL14419937 | 0.85 | FFAR2 (0.52) | CCNE1CDK2CDK4CDK1LMNA | |
| Hydrochloric Acid SCHEMBL28108629 | 0.83 | CCNE1 (0.43) | CCNE1CDK2CDK4CDK1LMNA | |
| SCHEMBL6078335 | 0.83 | CA2 (0.53) | CCNE1CDK2CDK4CDK1LMNA | |
| SCHEMBL10154046 | 0.82 | CA12 (0.54) | CCNE1CDK2CDK4CDK1LMNA | |
| SCHEMBL15882463 | 0.82 | CCNE1 (0.44) | CCNE1CDK2CDK4CDK1LMNA | |
| SCHEMBL16731877 | 0.82 | CCNE1 (0.49) | CCNE1CDK2CDK4CDK1LMNA | |
| SCHEMBL10233482 | 0.81 | OGA (0.45) | CCNE1CDK2CDK4CDK1LMNA | |
| SCHEMBL30760419 | 0.79 | CA1 (0.49) | CCNE1CDK2CDK4CDK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092053-A1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4681774-A2 | KHK INHIBITORS | Gilead Sciences, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4313967-B1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-12410160-B2 | KHK inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| CN-115745910-B | Chemical compound | 安塔比奥公司 | 2025-05-27 | — | — | CN | disclosed |
| US-20240190860-A1 | 8-CYCLO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-06-13 | — | — | US | disclosed |
| EP-4313967-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-4313956-A1 | 8-CYCLO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2024-02-07 | — | — | EP | disclosed |
| EP-4073073-B1 | THIENOPYRIMIDINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | CHIESI FARM SPA (IT) | 2023-12-06 | — | — | EP | disclosed |
| CN-117120429-A | KHK inhibitor | 吉利德科学公司 | 2023-11-24 | — | — | CN | disclosed |
| WO-2007006760-A1 | DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007007886-A1 | AN OXIME DERIVATIVE AND PREPARATIONS THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007006814-A1 | UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
| EP-1723128-A1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2006-11-22 | — | — | EP | disclosed |
| US-20060183756-A1 | Pyrrazolo-pyrimidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-08-17 | — | — | US | disclosed |
| WO-2006084634-A1 | PYRAZOLO-PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-08-17 | — | — | WO | disclosed |
| WO-2005066145-A1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2005-07-21 | — | — | WO | disclosed |
| US-5360813-A | Inhibitors of ergosterol biosynthesis | J. URIACH & CIA. S.A. (ES) | 1994-11-01 | — | — | US | disclosed |
| US-5344839-A | Imidazole or triazole compounds | J. URIACH & CIA. S.A. (ES) | 1994-09-06 | — | — | US | disclosed |
| EP-0480215-A1 | New sulfonamides as antifungal agents | J. URIACH & CIA. S.A. (ES) | 1992-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183756-A1 | Pyrrazolo-pyrimidine derivatives | GRM1, GRM2, GRM3 | CCNE1 2427/4885CDK2 506/4885CDK4 533/4885 |
| US-20260092053-A1 | KHK INHIBITORS | KHK, SLC5A2, HK1 | CCNE1 4317/4885CDK2 2411/4885CDK4 2297/4885 |
| US-12410160-B2 | KHK inhibitors | KHK, KHDRBS1, NADK | CCNE1 2915/4885CDK2 519/4885CDK4 1215/4885 |
| US-20240190860-A1 | 8-CYCLO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | LPAR2, LPAR5, LPAR1 | CCNE1 2107/4885CDK2 298/4885CDK4 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.